Mergers & Acquisitions
By The Online Investor Staff, updated Sat., Sep. 19, 7:48 AM
Slide #98. Ionis Pharmaceuticals, Inc. — Akcea Therapeutics, Inc.
| Acquirer: |
Ionis Pharmaceuticals, Inc. (IONS) |
| Acquiree: |
Akcea Therapeutics, Inc. (AKCA) |
| Details: |
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. This corresponds to a total transaction value of approximately $500 million on a fully diluted basis. The transaction has been approved by the Ionis and Akcea Boards of Directors, and by the independent Affiliate Transactions Committee of Akcea's Board of Directors. Akcea's Board of Directors has recommended to shareholders of Akcea that they tender their shares into the tender offer. |
Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. Co.'s commercial medicines are: SPINRAZA, a survival motor neuron-2, directed antisense medicine for the treatment of spinal muscular atrophy in pediatric and adult patients; TEGSEDI, an RNA-targeted medicine designed to reduce the production of TTR protein; and WAYLIVRA, an antisense medicine designed to treat people with rare, hereditary diseases. Co. has drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for various forms of TTR amyloidosis.
IONS SEC Filing Email Alerts Service
Open the IONS Page at The Online Investor »
Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. Co.'s commercial medicines are: SPINRAZA, a survival motor neuron-2, directed antisense medicine for the treatment of spinal muscular atrophy in pediatric and adult patients; TEGSEDI, an RNA-targeted medicine designed to reduce the production of TTR protein; and WAYLIVRA, an antisense medicine designed to treat people with rare, hereditary diseases. Co. has drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for various forms of TTR amyloidosis.
IONS SEC Filing Email Alerts Service
Open the AKCA Page at The Online Investor »
| Company Name: |
| Ionis Pharmaceuticals Inc |
| Website: |
| www.ionispharma.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding IONS: |
| 55 |
| Total Market Value Held by ETFs: |
| $860.90M |
| Total Market Capitalization: |
| $7.23B |
| % of Market Cap. Held by ETFs: |
| 11.90% |
|
| Company Name: |
| Akcea Therapeutics Inc |
| Website: |
| www.akceatx.com |
| Sector: |
| Biotechnology |
| Number of ETFs Holding AKCA: |
| 23 |
| Total Market Value Held by ETFs: |
| $53.61M |
| Total Market Capitalization: |
| $1.84B |
| % of Market Cap. Held by ETFs: |
| 2.91% |
|
Quotes delayed 20 minutes
|
